Navigation Links
Hernia Publishes a Unique Three Year Pre-Clinical Study of absorbable TIGR® Matrix Surgical Mesh Versus a Permanent Mesh
Date:10/6/2011

SINGAPORE, Oct. 6, 2011 /PRNewswire/ -- Novus Scientific today announced the peer-reviewed publication of unique pre-clinical data on TIGR® Matrix Surgical Mesh – the world's first long-term absorbable surgical mesh.

The study, which was presented Online First in Hernia - The World Journal of Hernia and Abdominal Wall Surgery, describes the results of three years of functional implantation of TIGR® Matrix versus a permanent mesh in a sheep model.

This is the longest preclinical evidence ever published on surgical mesh, and it reveals key differences in outcome when comparing TIGR® Matrix to a permanent mesh. As TIGR® Matrix was absorbed over time, it was replaced by connective tissue that had higher collagen content than that surrounding the permanent control mesh. Over time, the foreign-body response to TIGR® Matrix declined significantly while it remained persistent in the control group.

"As TIGR® Matrix is the worlds first long-term absorbable mesh and also the first surgical mesh product with time-dependent mechanical characteristics, we wanted to substantiate how the unique design affects the tissue in terms of regenerated structure and stability." – said Henrik Hjort, first author and co-inventor of TIGR® Matrix. "We believe that the dual-fibre mechanics and resultant gradually increasing compliance can lead to long-lasting results which are indicated by the lack of defect recurrences in this study. A range of clinical studies are underway to examine the results of repair using TIGR® Matrix in a variety of soft tissue reinforcement applications to further demonstrate the benefits to the surgical community."

As stated in the publication: "As the resorbable test mesh gradually degraded it was replaced by a newly formed collagen matrix with an increasing ratio of collagen type I/III, indicating a continuous remodeling of the collagen towards a strong connective tissue." Furthermore: "The general connective tissue layer formed was thicker around the test mesh compared to the control." Hjort H, et al. (2011) Hernia. doi: 10.1007/s10029-011-0885-y.

The study was performed at Biomatech, an independent contract research company that is part of the NAMSA group.

Hernia – The World Journal of Hernia and Abdominal Wall Surgery is published by Springer (www.springerlink.com) and the article link can be found here: http://www.springerlink.com/content/c033k26015677312/

TIGR® Matrix  Surgical Mesh is available for sale in the U.S. and Europe.

About Novus Scientific

Novus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of resorbable synthetic medical devices. For comprehensive information visit our PRESSROOM: http://www.mynewsdesk.com/pressroom/novus-scientific

TIGR® is a trademark of Novus Scientific Pte. Ltd

CONTACT:  
Mark Hawthorne: +44 7748 988705 - mark.hawthorne@novusscientific.com


'/>"/>
SOURCE Novus Scientific
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
2. Reportlinker Adds Global Hernia Repair Devices Industry
3. Biomerix Ventral Hernia Repair Mesh Receives FDA 510(k) Clearance
4. Ethicon, Inc. Introduces Two Innovative Devices for Minimally Invasive Hernia Repair During American College of Surgeons (ACS) Annual Meeting
5. TIGR® Matrix Surgical Mesh - Exhibited Ahead of Anticipated CE Mark Approval at European Hernia Society 2011, Ghent, Belgium
6. MetroSouth Surgeon Pioneers Hybrid Treatment of Large Hiatal Hernias and Reflux
7. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
8. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
9. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
10. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
11. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, Gynaecology, ... expected to grow at a CAGR of 9.4% from 2017-2022 and ... at a CAGR of 9.5% from 2017 to 2027. The market ... ... benefit you Read on to discover how you can exploit ...
(Date:2/17/2017)... 2017 Arvinas LLC, a private biotechnology company ... degradation, today announced the presentation of new preclinical data ... poster session at the American Society of Clinical Oncology ... Orlando, FL. "The new ... the potential of PROTACs to drive durable and robust ...
(Date:2/17/2017)... and Markets has announced the addition of the "Pharmaceutical Contract Manufacturing ... ... the US, Canada , Japan , ... of World. Annual estimates and forecasts are provided for the period 2015 ... Market data and analytics are derived from primary and secondary research. ...
Breaking Medicine Technology:
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... software tools that allow for the electronic prescribing of controlled and non-controlled substances ... , Ninety percent of pharmacies in the United States now accept electronic prescriptions, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each person's mental functions, ... each and every seminar, session and class she offers. At the International ... which help energize creativity, focus mental functions, enhance athletic focus and skill sets, ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended ... all facets of clinical trial planning and management. Pharmica discussed the importance of ... In addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
(Date:2/17/2017)... ... 17, 2017 , ... Like most hospitals across the nation, Onslow Memorial Hospital ... the Hospital Readmission Reduction Program (HRRP), the return of a patient to the hospital ... the nation. While many providers are struggling to leverage limited resources and technology, Onslow ...
Breaking Medicine News(10 mins):